KPRX (Kiora Pharmaceuticals) Total Assets: $21.23 Mil (As of Mar. 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
34 GF Score
Price $2.54
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Total Assets?

Kiora Pharmaceuticals KPRX -0.78% 34 Total Assets is $21.23 Mil as of Mar. 2026. GuruFocus rates KPRX with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Kiora Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $21.23 Mil.

During the past 12 months, Kiora Pharmaceuticals's average Total Assets Growth Rate was -25.80% per year. During the past 3 years, the average Total Assets Growth Rate was -17.40% per year. During the past 5 years, the average Total Assets Growth Rate was -11.40% per year. During the past 10 years, the average Total Assets Growth Rate was 14.50% per year.

During the past 13 years, Kiora Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 217.20%. The lowest was -17.40%. And the median was 26.10%.

Total Assets is connected with ROA %. Kiora Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was -42.53%. Total Assets is also linked to Revenue through Asset Turnover. Kiora Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Kiora Pharmaceuticals  (NAS:KPRX) Total Assets Explanation

Total Assets is connected with ROA %.

Kiora Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-9.672/( (24.253+21.227)/ 2 )
=-9.672/22.74
=-42.53 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Kiora Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (24.253+21.227)/ 2 )
=0/22.74
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Kiora Pharmaceuticals Total Assets Related Terms

Kiora Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Total Assets Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.13 18.68 13.71 36.48 24.25

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.02 31.95 29.86 24.25 21.23
KPRX
34GF Score
Kiora Pharmaceuticals Inc KPRX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Kiora Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=16.127+8.127
=24.25

Kiora Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=13.935+7.293
=21.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $21.23 Mil mean?
Kiora Pharmaceuticals (KPRX) has a Total Assets of $21.23 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Total Assets too high?
Kiora Pharmaceuticals' current Total Assets is $21.23 Mil. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Total Assets compare to PHIO and PBM?
Kiora Pharmaceuticals' Total Assets of $21.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Total Assets is $21.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Total Assets of $21.23 Mil. The current Total Assets is $21.23 Mil. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Total Assets is $21.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for KPRX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.54
Price